Evidence map›Paper›PMID 39713544›Full record

ArticleAdvances in laboratory medicine2024

Pharmacogenetics of colorectal cancer in a third-level hospital in Valencia.

Ana Comes-Raga, Luis Sendra Gisbert, Goitzane Marcaida-Benito, Salvador F Aliño Pellicer, María José Herrero Cervera

Abstract read
In one paragraph

Article in Advances in laboratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana Comes-RagaDepartment of Clinical Biochemistry, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
Luis Sendra GisbertGene Therapy and Pharmacogenomics Research Group, Department of Pharmacology, Universitat de València and IIS La Fe, Valencia, Spain.
Goitzane Marcaida-BenitoDepartment of Clinical Biochemistry, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
Salvador F Aliño PellicerGene Therapy and Pharmacogenomics Research Group, Department of Pharmacology, Universitat de València and IIS La Fe, Valencia, Spain.
María José Herrero CerveraGene Therapy and Pharmacogenomics Research Group, Department of Pharmacology, Universitat de València and IIS La Fe, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Genetic variants with associated pharmacokinetic and pharmacodynamic effects have an impact on the development of adverse drug reactions and survival of patients with colorectal cancer. Methods: A selection of genetic variants was performed according to the established chemotherapy and the pharmacogenetic databases. Genotyping was performed using MassArray technology (Agena Bioscience). Variant-toxicity and survival-genotype correlations were assessed using logistic regression (SPSS v.28.0.1.1). Results: Genotyping of 25 SNPs was performed in 96 patients. In relation to the Conclusions: The population frequencies obtained in our study for rs1801160 and rs75017182 (

Indexed as

colorectal cancergenotypingpharmacogeneticspolymorphismprecision medicinevariant

Identifiers

PMID39713544
PMCPMC11661530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.